Zacks.com on MSN3mon
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
AbbVie ABBV announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular ...
AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
Yahoo Finance2d
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British ...
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...
Hosted on MSN7mon
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
FDA’s Priority Tag to AbbVie’s Epkinly for Follicular Lymphoma: AbbVie announced that the FDA has granted priority review to a sBLA seeking approval for Epkinly (epcoritamab) for relapsed or ...
12 Analysts Have This To Say About Genmab
Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...
AbbVie Falters Despite Progress in Lymphoma Treatment
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Genmab’s Strong Performance and Strategic Positioning: A Buy Rating with $50 Price Target
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at ...
Brokers Issue Forecasts for AbbVie’s Q3 Earnings (NYSE:ABBV)
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
BMO Capital Markets Boosts AbbVie (NYSE:ABBV) Price Target to $220.00
AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...
Stockhouse3d
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with ...